All Guidance

Radiographic (Ankylosing Spondylitis) and Non-radiographic Axial Spondyloarthritis (ASp) LSCMMG Recommended Biologic Pathway

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance. 

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).

Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.

For Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight in adults Information for prescribers - to be read in conjunction with the SPC

Treatment of active rheumatoid arthritis and active psoriatic arthritis.

This guideline comprises a flow chart outlining a stepwise approach to the management of psoriasis in adults and in children and young people. The guideline also includes relevant treatment review periods and referral criteria.

Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease

N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs

Guidance on consensus approaches to managing Palliative Care Symptoms

Licensed: Severe active rheumatoid arthritis, including juvenile forms, Wilson's disease (hepatolenticular degeneration) in adults and children (0 to 18 years).

To extend life or the time to mechanical ventilation for adult patients with amyotrophic lateral sclerosis (ALS) 1,2, variant of Motor Neurone Disease (MND). Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other forms of MND. Riluzole should only be initiated by a neurological specialist with expertise in the management of MND (as per NICE TA 20, 2001)

It is expected that most patients will be managed by secondary care however this guideline is those patients who need to be managed in community

Licensed: Rheumatoid arthritis; ulcerative colitis, Crohn’s disease in adults and children
Unlicensed: Sero-negative spondyloarthropathy including psoriatic arthritis and psoriasis.